Oxford Group Launches PGM-Based Cancer Test under UK's Stratified Medicine Program | GenomeWeb

A group at the University of Oxford has begun offering a sequencing-based cancer test that uses Life Technologies' Ion Torrent PGM — the first sequencing-based product developed under the UK's Stratified Medicine Program.

About a year and a half ago, the UK's Technology Strategy Board provided funding for six tumor-profiling projects, three of which were sequencing-based, with a total of £5.8 million ($9.4 million) under its Stratified Medicine Program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.